244 related articles for article (PubMed ID: 32201138)
1. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan.
Qamar FN; Yousafzai MT; Khaliq A; Karim S; Memon H; Junejo A; Baig I; Rahman N; Bhurgry S; Afroz H; Sami U
Vaccine; 2020 Apr; 38(19):3518-3523. PubMed ID: 32201138
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
Longley AT; Date K; Luby SP; Bhatnagar P; Bentsi-Enchill AD; Goyal V; Shimpi R; Katkar A; Yewale V; Jayaprasad N; Horng L; Kunwar A; Harvey P; Haldar P; Dutta S; Gidudu JF
Clin Infect Dis; 2021 Aug; 73(4):e927-e933. PubMed ID: 33502453
[TBL] [Abstract][Full Text] [Related]
4. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
[TBL] [Abstract][Full Text] [Related]
5. Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
Batool R; Yousafzai MT; Qureshi S; Muhammad S; Qazi I; Sadaf T; Ashorn P; Qamar FN
Vaccine; 2023 Aug; 41(37):5376-5382. PubMed ID: 37463829
[TBL] [Abstract][Full Text] [Related]
6. Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine.
Yousafzai MT; Qamar FN; Shakoor S; Saleem K; Lohana H; Karim S; Hotwani A; Qureshi S; Masood N; Rauf M; Khanzada JA; Kazi M; Hasan R
Clin Infect Dis; 2019 Feb; 68(Suppl 1):S16-S21. PubMed ID: 30767003
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
8. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Improve Coverage of Typhoid Conjugate Vaccine (TCV) Immunization Campaign in Karachi, Pakistan.
Qamar FN; Batool R; Qureshi S; Ali M; Sadaf T; Mehmood J; Iqbal K; Sultan A; Duff N; Yousafzai MT
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33228111
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
Batool R; Tahir Yousafzai M; Qureshi S; Ali M; Sadaf T; Mehmood J; Ashorn P; Naz Qamar F
Vaccine; 2021 Sep; 39(40):5858-5865. PubMed ID: 34465474
[TBL] [Abstract][Full Text] [Related]
11. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
[TBL] [Abstract][Full Text] [Related]
12. Coverage survey of typhoid conjugate vaccine among children aged 6 months to 15 years in an urban slum settlement of Lyari Town Karachi, Pakistan.
Batool R; Qureshi S; Haq Z; Yousafzai MT; Salam RA; Ali R; Sadaf T; Ali M; Qamar FN
PLoS One; 2023; 18(8):e0289582. PubMed ID: 37549155
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
[TBL] [Abstract][Full Text] [Related]
15. A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India.
Reddy R; Reddy B; Sarangi V; Reddy S; Ella R; Vadrevu KM
Hum Vaccin Immunother; 2022 Dec; 18(1):1947761. PubMed ID: 34242128
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
17. Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
Date K; Shimpi R; Luby S; N R; Haldar P; Katkar A; Wannemuehler K; Mogasale V; Pallas S; Song D; Kunwar A; Loharikar A; Yewale V; Ahmed D; Horng L; Wilhelm E; Bahl S; Harvey P; Dutta S; Bhatnagar P
Clin Infect Dis; 2020 Jul; 71(Suppl 2):S172-S178. PubMed ID: 32725235
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
[TBL] [Abstract][Full Text] [Related]
19. Knowledge, attitudes, and practices of the general population of Pakistan regarding typhoid conjugate vaccine: findings of a cross-sectional study.
Tahir MJ; Zaman M; Saffi J; Asghar MS; Tariq W; Ahmed F; Islam R; Farooqui US; Ullah I; Saqlain M; Ullah K; Ahmed A
Front Public Health; 2023; 11():1151936. PubMed ID: 37333546
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
